Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Bristol-myers Squibb Holdings Ireland

Van N Nguyen

Makonen Belema

Nicholas A Meanwell

Denis R St Laurent

Omar D Lopez

Lawrence B Snyder

Jeffrey Lee Romine

Fukang Yang

Andrew Charles Good

Alain Martel

Jason T Goodrich

Lawrence G Hamann

Edward H Ruediger

David R Langley

Carol Bachand

Daniel H Deon

Clint A James

Rico Lavoie

Gan Wang

John A Bender

Yuping Qiu

Piyasena Hewawasam

Michael H Serrano-Wu

Zhong Yang

Ningning Xu

John F Kadow

Alan Xiangdong Wang

Xuejie Yang

Qi Chen

Ramesh Kakarla

Annapurna Pendri

Mark George Saulnier

Robert G Gentles

Min Ding

Anne Marinier

David Bertil Frennesson

Yong Tu

Manoranjan Panda

Francis Beaulieu

Brett R Beno

Yunhui Zhang

Srinivasan Thangathirupathy

Min Gao

Amy Mae Bunker

Hasibur Rahaman

Michael J Smith

Carl Ouellet

Guo Li

Rajesh Onkardas Bora

John E Leet

Stephan Roy

Selvakumar Kumaravel

Samayamunthula Venkata Satya Arun Kumar Gupta

Julie A Lemm

Robert A Fridell

Donald R O'Boyle, Ii

Jayne Kapur

Mallikarjuna Rao Mettu

Roshan Yadavrao Nimje

John A Easter

Bao-Ning Su

Shilpa Maheshwarappa Holehatti

Christopher Zusi

Denis R STLAURENT

Belema Makonen

Ramesh Kakaria

Donald R Ii O'BOYLE

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. 

Growing community of inventors

Meriden, CT, United States of America

Van N Nguyen